N. Higo et al., CUTANEOUS METABOLISM OF NITROGLYCERIN INVITRO .2. EFFECTS OF SKIN CONDITION AND PENETRATION ENHANCEMENT, Pharmaceutical research, 9(3), 1992, pp. 303-306
The effects of skin storage. skin preparation, skin pretreatment with
a penetration enhancer, and skin barrier removal by adhesive tape-stri
pping on the concurrent cutaneous transport and metabolism of nitrogly
cerin (GTN) have been studied in vitro using hairless mouse skin. Stor
ing the skin for 10 days at 4-degrees-C did not alter barrier function
to total nitrate flux [GTN + 1.2-glyceryl dinitrate (1,2-GDN) + 1,3-g
lyceryl dinitrate (1,3-GDN)]. However, metabolic function was signific
antly impaired and suggested at least fivefold loss of enzyme activity
. Heating skin to 100-degrees-C for 5 min appreciably damaged hairless
mouse skin barrier function. The ability to hydrolyze GTN was still p
resent, however, and remained constant over the 10-hr experimental per
iod, in contrast to the "control," which showed progressively decreasi
ng enzymatic function with time. Pretreatment of hairless mouse skin i
n vivo (prior to animal sacrifice, tissue excision, and in vitro trans
port/metabolism studies) with 1-dodecylazacycloheptan-2-one (Azone), a
putative penetration enhancer, significantly lowered the skin barrier
to nitrate flux (relative to the appropriate control). Again, barrier
perturbation resulted in essentially constant metabolic activity over
the observation period. The ratio of metabolites formed (1,2-GDN/1,3-
GDN) was increased from less than unity to slightly above 1 by the Azo
ne treatment. Adhesive tape-stripping gradually destroyed skin barrier
function by removal of the stratum corneum. The effects of 15 tape-st
rips were identical to those of Azone pretreatment: a greatly enhanced
flux, a constant percentage formation of metabolites over 10 hr (once
again), and an increase in the 1,2-GDN/1,3 GDN ratio. Overall, the ex
periments caution that, for transdermal drug delivery candidates susce
ptible to skin metabolism, the status of barrier function (enhancer pr
etreated, skin damage or disease, etc.) may significantly affect syste
mic availability.